Ketorolac Tromethamine 5 mg/mL Solution/ Drops
Other active recalls for Ketorolac Tromethamine (different manufacturers) — 3 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Nonsteroidal Anti-inflammatory Drug class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- That's actually how ketorolac has to be used — the rules say treatment must always start with an injection, either into a vein or a muscle. The oral tablets are only for continuing...
- Why did my doctor give me a shot first instead of just pills?
- Ketorolac is actually quite hard on your stomach, kidneys, and cardiovascular system when used beyond 5 days — the risks of serious bleeding, ulcers, and other complications go up...
- Why can I only take this for 5 days? My pain might last longer than that.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Ketorolac Tromethamine — tap one for details:
Ketorolac Tromethamine may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F5UM2KM3W7
Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 9T1C662FKS
A synthetic detergent and emulsifier derived from octylphenol. It helps blend water and oil-based ingredients together and improves how the medicine disperses in the body, commonly used in injectable and topical formulations.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $2.30 | $22.99 / 10 ml |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Ketorolac Tromethamine 5 mg/mL 65145-0140-01 | Caplin | 1 bottle | $1.358 | AT | Availability likely | — |
| Ketorolac Tromethamine 5 mg/mL 42571-0137-25 | Micro | 5 ml | $1.448 | AT | Availability likely | — |
| Ketorolac Tromethamine 5 mg/mL 60505-1003-01 | Apotex | 1 bottle | $1.448 | AT | Availability likely | — |
| Ketorolac Tromethamine 5 mg/mL 61314-0126-05 | Sandoz | 5 ml | $1.448 | AT | Availability likely | — |
| Ketorolac Tromethamine 5 mg/mL 65145-0139-01 | Caplin | 1 bottle | $1.448 | AT | Availability likely | — |
| Ketorolac Tromethamine 5 mg/mL 47335-0220-90 | Sun | 1 bottle | $1.475 | — | FDA listed | — |
| Acular 5 mg/mL 00023-2181-05 | Allergan, | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 47335-0219-90 | Sun | 1 bottle | — | — | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mLthis 47335-0221-90 | Sun | 1 bottle | — | — | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 50090-2746-00 | A-S | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 63187-0628-05 | Proficient | 1 bottle | — | — | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 63187-0777-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 65145-0138-01 | Caplin | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 65862-0770-05 | Aurobindo | 1 bottle | — | — | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 67296-2210-01 | Redpharm | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 67296-2253-01 | Redpharm | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 68071-2252-05 | NuCare | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 68071-2400-05 | NuCare | 1 bottle | — | — | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 68071-3684-05 | NuCare | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 68071-3880-05 | NuCare | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 68788-8549-05 | Preferred | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 69315-0322-03 | Leading | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 70512-0790-03 | SOLA | 1 bottle | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 71205-0296-05 | Proficient | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 72162-2384-02 | Bryant | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 72189-0335-05 | Direct | 5 ml | — | AT | FDA listed | — |
| Ketorolac Tromethamine 5 mg/mL 67296-2318-05 | Redpharm | 1 bottle | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 47335-0221-90 You're viewing this | 1 BOTTLE, DROPPER in 1 CARTON (47335-221-90) / 10 mL in 1 BOTTLE, DROPPER | 2018-03-13 | Active |
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for: The treatment of inflammation following cataract surgery.
( 1 ) The temporary relief of ocular itching due to seasonal allergic conjunctivitis. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION One drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye(s) four times a day for relief of ocular itching due to seasonal allergic conjunctivitis. For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
( 2.1 )
2.1Recommended Dosing Patient Dosing The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day to the affected eye(s) for relief of ocular itching due to seasonal allergic conjunctivitis. For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of ketorolac tromethamine ophthalmic solution should be applied to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
2.2Use with Other Topical Ophthalmic Medications Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows: 5 mL size bottle filled with 3 mL of solution 5 mL size bottle filled with 5 mL of solution 10 mL size bottle filled with 10 mL of solution Ophthalmic solution containing 5 mg/mL ketorolac tromethamine. ( 3 ) 5 mL size bottle filled with 3 mL of solution 5 mL size bottle filled with 5 mL of solution 10 mL size bottle filled with 10 mL of solution
⛔ Contraindications ▾
4 CONTRAINDICATIONS Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation. Hypersensitivity to any component of this product. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Delayed healing ( 5.1 ) Cross-sensitivity or hypersensitivity ( 5.2 ) Increased bleeding time due to interference with thrombocyte aggregation ( 5.3 ) Corneal effects including keratitis ( 5.4 )
5.1Delayed Healing Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
5.2Cross-Sensitivity or Hypersensitivity There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
5.3Increased Bleeding Time With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti- inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.
5.4Corneal Effects Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health. Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening.
Topical NSAIDs should be used with caution in these patients. Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
5.5Contact Lens Wear Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most frequent adverse reactions reported by up to 40% of patients participating in clinical trials have been transient stinging and burning on instillation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1Clinical Studies Experience Because cli nical studies are conducted under wi dely var ying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to t he rates in the clinical studies of another drug and may not reflect t he rates observed in practice. The most fr equent adverse react ions reported with the use of k etorolac tro meth a mine ophthal mic solutio ns have been tra nsient stin gi ng and burni ng on instillation. These reactions were reported by up to 40% of patie nts partici pating in clinic al t rials.
Other adverse reactions occurring approxi mately 1 to 10% of the ti me during tre at ment with ketor olac tr ometh a mine ophthal mic solutio ns inc luded aller gic reactions, corneal ede ma, iritis, ocular inflammation, ocular ir rit ati on, super fici al ker atitis, and super ficial ocular in fectio ns. Other adverse reactions reported rarely with the use of ketorolac tro metha mine ophthal mic solutio ns included: c orneal infiltrates, corneal ulcer, eye dry ness, headac hes , and visual disturbance (blurry vision).
6.2Postmarketing Experience The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5% or a combination of these factors, include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown [see Warnings and Precautions ( 5.2 , 5.4 )].
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Teratogenic Effects. P regnancy Category C Pregnancy Category C: Ketorolac tr o metha min e, ad ministered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/ kg/day, respectively. These doses are approxi mately 100 ti mes and 250 ti mes higher respectively than the max i m um recom mended hu man topical op hthal mic daily d ose of 2 mg (5 mg / mL x 0.05 mL/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis.
Additionally, when ad ministered to rats after Day 17 of gestation at oral doses up to 1.5 mg/ k g/day (approxi mately 40 ti mes the typical hu man topical ophthal mic daily dose), ketorolac tro me tha mine resulted in dystocia and increased pup mortality. There are no adequate a nd well-controlled studies in pregnant w o men. Keto ro lac t ro met ham ine op htha lm ic so lut i on should be used during pregnancy only if the potential bene fit j usti fies the p otential risk to the fetus.
Nonterato genic Effect s: Because of the known effects of prostaglandin-inhibiting drugs on the fetal c ardio vascul ar syst em (closure of the ductus art eriosu s), the use of keto ro lac t ro met ham ine op htha lm ic so lut i on during late pregnancy should be avoided.
8.3Nursing Mothers Because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.
8.4Pediatric Use Safety and efficacy in pediatric patients bel ow t he age of 2 have not been esta blished.
8.5Geriatric Use No overall clinical di fferences in sa fety or effectiveness have been observed between elderly and other ad ult patie nts.
🤰 Pregnancy ▾
8.1Pregnancy Teratogenic Effects. P regnancy Category C Pregnancy Category C: Ketorolac tr o metha min e, ad ministered during organogenesis, was not teratogenic in rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/ kg/day, respectively. These doses are approxi mately 100 ti mes and 250 ti mes higher respectively than the max i m um recom mended hu man topical op hthal mic daily d ose of 2 mg (5 mg / mL x 0.05 mL/drop, x 4 drops x 2 eyes) to affected eyes on a mg/kg basis.
Additionally, when ad ministered to rats after Day 17 of gestation at oral doses up to 1.5 mg/ k g/day (approxi mately 40 ti mes the typical hu man topical ophthal mic daily dose), ketorolac tro me tha mine resulted in dystocia and increased pup mortality. There are no adequate a nd well-controlled studies in pregnant w o men. Keto ro lac t ro met ham ine op htha lm ic so lut i on should be used during pregnancy only if the potential bene fit j usti fies the p otential risk to the fetus.
Nonterato genic Effect s: Because of the known effects of prostaglandin-inhibiting drugs on the fetal c ardio vascul ar syst em (closure of the ductus art eriosu s), the use of keto ro lac t ro met ham ine op htha lm ic so lut i on during late pregnancy should be avoided.
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and efficacy in pediatric patients bel ow t he age of 2 have not been esta blished.
🧓 Geriatric Use ▾
8.5Geriatric Use No overall clinical di fferences in sa fety or effectiveness have been observed between elderly and other ad ult patie nts.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Ketorolac tr o metha mine is a nonsteroidal ant i-inflammatory drug which, when a d ministered syste micall y, has de monstrated anal gesic, a nti-inflam matory, and anti-pyretic activity. The mechani sm of its action is thought to be due to i ts ability to inhibit prostaglandin biosynthesis.
12.3Pharmacokinetics Two drops of 0.5% ketorolac tro metha mine ophthal mic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved a mean ketorolac concentration of 95 ng/ mL in the aqueous h u mor of 8 of 9 eyes tested (range 40 to 170 ng/mL). One drop of 0.5% ketorolac tro metha mine ophthal mic solution was instilled into 1 eye and 1 drop of vehicle into the other eye TID in 26 healthy subjects. Five (5) of 26 subjects had dete ctable concent ratio ns of ketorol ac in th eir plas ma (range 11 to 23 ng/mL) at Day 10 during topical ocular treat ment.
The range of concent rations following TID dosing of 0.5% ketorolac tro metha mi ne ophthal mic solution are approxi mately 4 to 8% of the steady state mean min i m um plas ma concentration observed following four ti mes daily oral a d ministration of 10 mg ketorolac in hu mans (290 ± 70 ng/mL).
🧬 Mechanism of Action ▾
12.1Mechanism of Action Ketorolac tr o metha mine is a nonsteroidal ant i-inflammatory drug which, when a d ministered syste micall y, has de monstrated anal gesic, a nti-inflam matory, and anti-pyretic activity. The mechani sm of its action is thought to be due to i ts ability to inhibit prostaglandin biosynthesis.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Ketorolac tromethamine ophthalmic solution 0.5% is supplied sterile in white opaque LDPE dropper bottles with white opaque plug and sealed with gray pantone opaque pilfer-proof caps as follows: 3 mL in 5 mL bottle NDC 47335-219-90 5 mL in 5 mL bottle NDC 47335-220-90 10 mL in 10 mL bottle NDC 47335-221-90 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light.
📋 Description ▾
11 DESCRIPTION Keto ro lac t ro met ham ine op htha lm ic so lut i on 0.5% is a m ember of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthal mic use. Its che mical na me is (±)-5-Benzoyl-2, 3-dihydro-1H pyrrolizi ne-1-carboxylic acid co m pound with 2-a mino-2-(hydroxy methyl)-1,3-propanediol ( 1:1) and it has the following structure: Keto ro lac t ro met ham ine op htha lm ic so lut i on is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. Keto ro lac t ro met ham ine op htha lm ic so lut i on is a race mic m ixture of R-(+) and S-(-)- ketor olac tro metha mine.
Ketorol ac tro methamine may exist in t hree cr ystal for ms. All for ms are equally soluble in water. The pKa of ketorolac is 3.5.
This white to o ff-white c rystalline su bstance discolors on prolonged exposure to light. The m o lecular weight of ketorolac tro metha mine is 376.41. The os molality of keto ro lac t ro met ham ine op htha lm ic so lut i on is 290 m O s mol/kg.
Each mL of ketorolac tromethamine ophthalmic solution contains: Active: ketorolac tromethamine USP 0.5%. Preservative: benzalkonium chloride solution (50%) NF 0.02%. Inactives: edetate disodium USP 0.1%; octoxynol 40; water for injection USP; sodium chloride USP; hydrochloric acid NF and/or sodium hydroxide NF to adjust the pH. ketorolac-structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION
17.1Slow or Delayed Healing Patie nts sh ould be in fo r med of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).
17.2Avoiding Contamination of the Product Patie nts sh ould be in str ucted to avoid allow ing the tip of the bottle to co ntact the eye or surrounding structures because this could cause the tip to beco me cont a m inated by common bacteria kn own to cause ocular infections. Serious da mage to the eye and subsequent loss of vision may result from using contaminated solutions. Also, to avoid the potential for cross-conta mina tion, the patient should be advised to use one bottle for e ach eye foll owing bil ate ral ocular s u rgery.
The use of the s a me bottle of topic al eye drops for both eyes following bilateral ocular surgery is not recom mend ed.
17.3Contact Lens Wear Patients should be advised that keto ro lac t ro met ham ine op htha lm ic so lut i on should not be ad ministered while wearing contact lenses.
17.4Intercurrent Ocular Conditions Patients should be advised that if they develop an intercurrent ocular condition (e.g., trau ma or infection) or have ocular surgery, they should i mmediately seek their physician’s advice concerning the continued use of keto ro lac t ro met ham ine op htha lm ic so lut i on.
17.5Concomitant Topical Ocular Therapy Patie nts sh ould be advi sed that if m ore than one topical op ht hal mic medication is being used, the medicines should be ad ministered at least 5 minutes apart. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 PJPI0496A ISS. 07/2017